Immunomodulator

A medicine that calms down the immune system, such as azathioprine, mercaptopurine or methotrexate. Often called an immunosuppressant.

Related words combination therapy immunosuppressant thiopurine azathioprine mercaptopurine methotrexate

Topics Immunosuppressants

Questions people ask

Why might I take azathioprine or methotrexate alongside a biologic?

The 2025 BSG guideline recommends starting infliximab or adalimumab together with a thiopurine to reduce the chance of the body making antibodies against the biologic. Cochrane reviews found infliximab plus azathioprine or mercaptopurine probably works better than a thiopurine alone. Crohn's & Colitis UK also explains that methotrexate can reduce these antibodies.

Sources

Why might I be given azathioprine alongside infliximab?

The SONIC trial found that people who had not had these drugs before did better on infliximab plus azathioprine together than on either alone: about 57% were in remission without steroids at 26 weeks, against 44% on infliximab alone. The European and UK guidelines draw on trials like this. Your team will discuss the extra monitoring and side effects of using two medicines.

Sources

Am I entitled to the free flu jab and COVID booster?

Crohn's & Colitis UK says having Crohn's does not on its own make you eligible for the NHS flu, COVID-19 booster or RSV vaccines, but taking medicines that weaken the immune system may. Examples include azathioprine, mercaptopurine, methotrexate, biologics, newer targeted tablets and higher doses of steroids. The NHS flu page lists people with a weakened immune system among those offered the vaccine. Ask your GP or IBD team if you are unsure.

Sources

Why does my team check drug levels and antibodies on infliximab or adalimumab?

Some people's bodies make antibodies against infliximab or adalimumab, which can stop the medicine working. Crohn's & Colitis UK says your team may check the level of medicine and antibodies in your blood. The 2025 BSG guideline says these tests can help decide whether to adjust treatment or switch to a different medicine, and NHS Lothian describes checking levels after starting and then at least yearly. Taking an immunomodulator alongside can lower the chance of antibodies.

Sources

What is the difference between 'step-up' and 'top-down' treatment?

Step-up means starting with simpler treatments such as steroids and only moving on to stronger medicines if those do not work. Top-down means starting a biologic early, usually infliximab together with an immunomodulator. The UK PROFILE trial found that, in newly diagnosed people with active Crohn's, top-down treatment led to far more steroid-free and surgery-free remission after a year, and fewer hospital stays and complications after five years. The 2025 BSG guideline now suggests early infliximab for moderate to severe Crohn's.

Sources

Where to read more

ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment

European Crohn's and Colitis Organisation (J Crohns Colitis) Guideline Oct 2024 For professionals

Europe's main expert guideline on which medicines to use for Crohn's disease, published as the first of a two-part set (the second covers surgery). It weighs up the trial evidence for steroids, immunosuppressants, biologics and newer tablets, including treatment of disease around the back passage. UK specialists use it alongside the BSG guideline.

Topics Medicines Biologics and newer medicines Immunosuppressants Around the bottom (perianal)

Jargon explained biologic immunomodulator induction maintenance de-escalation perianal fistula GRADE

The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update

ECCO and ESPGHAN (J Crohns Colitis) Guideline Feb 2021 For professionals

European children's gut specialists agreed how to treat Crohn's in children and teenagers. A key message is to spot early the children most likely to have a difficult course, such as those with disease around the bottom or narrowing or penetrating disease, so stronger treatment can start early and limit long-term bowel damage.

Topics Children and young people Medicines Diet and nutrition Biologics and newer medicines

Jargon explained paediatric penetrating disease stricturing disease exclusive enteral nutrition anti-TNF immunomodulator therapeutic drug monitoring

A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE)

The Lancet Gastroenterology & Hepatology Study May 2024 Patients and professionals

A large UK-led trial of 386 newly diagnosed adults. Starting straight away with infliximab plus an immunosuppressant ('top-down') kept 79% in remission without steroids or surgery for a year, compared with 15% using the usual 'step-up' approach of trying milder drugs first. There were also fewer flares, serious side effects and operations. A blood test meant to predict who needed strong treatment did not help. Free to read in full.

Topics Biologics and newer medicines Research About Crohn's disease

Jargon explained top-down treatment step-up treatment biomarker steroid-free remission top-down step-up immunomodulator randomised controlled trial

Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial

The Lancet Gastroenterology & Hepatology Study Oct 2020 Patients and professionals

A longer look back at the people in the LIR!C trial. It supported keyhole removal of the end of the small bowel as a real option for people with short, mainly inflamed (not narrowed) disease when standard medicines have not worked. In both groups, adding an immunosuppressant was linked to the benefit lasting longer.

Topics Surgery Biologics and newer medicines

Jargon explained retrospective hazard ratio immunomodulator

Infliximab, azathioprine, or combination therapy for Crohn's disease (SONIC)

New England Journal of Medicine Study Apr 2010 Patients and professionals

A landmark trial of 508 adults with moderate to severe Crohn's who had never had immunosuppressants or biologics. Infliximab and azathioprine together worked best: about 57% were in remission without steroids at 26 weeks, against 44% on infliximab alone and 30% on azathioprine alone. This is why many people starting infliximab are offered a second 'helper' drug alongside it.

Topics Biologics and newer medicines Immunosuppressants Research

Jargon explained combination therapy steroid-free remission mucosal healing randomised controlled trial

Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease

Cochrane Systematic review Oct 2015 Patients and professionals

Cochrane pooled the trials of azathioprine and mercaptopurine for keeping Crohn's quiet. Low-quality evidence suggests azathioprine works better than placebo, but side effects such as pancreatitis, low white cell counts, sickness and infections limit its use. More good-quality trials are needed.

Topics Immunosuppressants Research

Jargon explained thiopurine low-quality evidence adverse event remission placebo systematic review

Guideline review: 2025 British Society of Gastroenterology guidelines on inflammatory bowel disease in adults - Part 1: Crohn's disease

Frontline Gastroenterology (via PMC) Guide Nov 2025 For professionals

A readable summary of what the 2025 BSG guideline says about Crohn's. Key points: early 'top-down' infliximab with an immunomodulator for moderate to severe disease; avoiding long or repeated steroid courses; no longer suggesting immunomodulators alone; upadacitinib and risankizumab added; vedolizumab no longer routinely suggested; drug-level testing for anti-TNFs; early surgery as an option for limited ileocaecal disease; and offering early treatment after resection.

Topics Medicines Surgery Monitoring

Jargon explained top-down step-up therapeutic drug monitoring ileocaecal resection Rutgeerts score immunogenicity

Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease

Cochrane Systematic review Aug 2019 Patients and professionals

Looks at whether azathioprine or mercaptopurine help stop Crohn's coming back after an operation. The evidence is weak: they may be a little better than placebo, may cause more side effects than mesalazine-type drugs, and may be less effective than anti-TNF biologics, but no firm conclusions can be drawn.

Topics Immunosuppressants Surgery Research

Jargon explained postoperative recurrence low certainty evidence post-operative recurrence thiopurine 5-ASA anti-TNF

Search everything for "immunomodulator"